Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05006872
Other study ID # RTI2018-096935-A-100_rct
Secondary ID IB 4320/20 PI
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 6, 2021
Est. completion date April 30, 2023

Study information

Verified date February 2022
Source Fundació d'investigació Sanitària de les Illes Balears
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims at evaluating the effectiveness of an intervention based on the use of a mobile-device based system delivering automated, tailored brief text messages to offer support for medicine use and lifestyle recommendations alongside usual care to people with type 2 diabetes.


Description:

A list of patients registered in primary care centers of the Balearic Islands and potentially meeting the eligibility criteria will be obtained from electronic health records (EHRs). A research assistant will contact the potential participants via phone to invite them to the study and confirm eligibility. All eligible participants will complete informed consent followed by baseline assessment over the phone before randomization. Participants will be randomly allocated using a computer-generated randomization sequence. All participants will continue with their usual diabetes care including all medical visits, tests, and diabetes support programs throughout the study. In addition, the intervention group will receive the text messaging intervention. Control participants will receive usual care only. After twelve months of follow-up, all participants will complete post-intervention assessments via phone interview. Data on glycemic control (HbA1c) at baseline and post-intervention will be extracted from EHRs, as according to the protocol used for primary care providers in the Balearic Islands, patients with poor glycemic control (HbA1c >8% ) must request an HbA1c determination every six months. Results of the most recent determination will be extracted from electronic medical records. For those patients with no recorded HbA1c within the previous four months, the research assistant will contact the primary care center to arrange blood test analyses.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 741
Est. completion date April 30, 2023
Est. primary completion date March 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients registered in the Public Health Service of the Balearic Islands - With type 2 diabetes - At least one prescription of a glucose-lowering drug - With results of HbA1c>8% from 6 months prior to recruitment Exclusion Criteria: - Younger than 18 years old - With insulin treatment - Participating in another research study - Not living in the Balearic Islands at some point during the study development

Study Design


Related Conditions & MeSH terms


Intervention

Device:
DIABE-TEXT
Participants will receive 170 text messages in their mobile phones during twelve months.

Locations

Country Name City State
Spain Ignacio Ricci-Cabello Palma De Mallorca Balearic Islands

Sponsors (1)

Lead Sponsor Collaborator
Fundació d'investigació Sanitària de les Illes Balears

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other 14-point Mediterranean diet adherence screener (MEDAS-14) The score range from 0 to 14. A higher score means a higher adherence to Mediterranean diet. We classified participants as low adherents (=5), moderate adherents (6-9) or high adherents (=10). Baseline
Other 14-point Mediterranean diet adherence screener (MEDAS-14) The score range from 0 to 14. A higher score means a higher adherence to Mediterranean diet. We classified participants as low adherents (=5), moderate adherents (6-9) or high adherents (=10). 12 months
Other International Physical Activity Questionnaire (IPAQ) 6-items adapted from the short version of the IPAQ by the Public Health System of the Balearic Islands: https:// apps.caib.es/plasalutfront/formularios/ipaq/ipaq.xhtml Result options are: low, moderate or high level of physical activity Baseline
Other International Physical Activity Questionnaire (IPAQ) 6-items adapted from the short version of the IPAQ by the Public Health System of the Balearic Islands: https:// apps.caib.es/plasalutfront/formularios/ipaq/ipaq.xhtml Result options are: low, moderate or high level of physical activity 12 months
Primary Glycated Hemoglobin (HbA1c) (%) Extracted from electronic health records Baseline
Primary Glycated Hemoglobin (HbA1c) (%) Extracted from electronic health records 12 months
Primary Mean adherence to antidiabetic drugs (%) Medication possession ratio for antidiabetic drugs Baseline
Primary Mean adherence to antidiabetic drugs (%) Medication possession ratio for antidiabetic drugs 12 months
Secondary Adherence to oral antidiabetic medication (7 items ad hoc questionnaire) 7 points = adherent; <7 points = non-adherent Baseline
Secondary Adherence to oral antidiabetic medication (7 items ad hoc questionnaire) 7 points = adherent; <7 points = non-adherent 12 months
Secondary Health-related quality of life (EQ-5D-5L) EQ-5D-5L index score Baseline
Secondary Health-related quality of life (EQ-5D-5L) EQ-5D-5L index score 12 months
Secondary Self-efficacy to manage Diabetes (DSES-S) The score for each item is the number circled. If two consecutive numbers are circled, code the lower number (less self-efficacy). If the numbers are not consecutive, do not score the item. The score for the scale is the mean of the eight items. If more than two items are missing, do not score the scale. Higher number indicates higher self-efficacy. Baseline
Secondary Self-efficacy to manage Diabetes (DSES-S) The score for each item is the number circled. If two consecutive numbers are circled, code the lower number (less self-efficacy). If the numbers are not consecutive, do not score the item. The score for the scale is the mean of the eight items. If more than two items are missing, do not score the scale. Higher number indicates higher self-efficacy. 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2